Vulnerable Patient Meeting (VPM)
The VPM (Vulnerable Patient Meeting, initially known as Vulnerable Plaque Meeting) was hosted by Cardialysis annually between 2002-2019. The VPM was a non-for-profit meeting which was generously supported by educational grants from the pharmaceutical and device industries with products targetting the detection and treatment of vulnerables coronary plaques and patients. The VPM Conference was compliant with the Eucomed Code of Ethical Business Practice.
The VPM hosted approximately 75 to 100 attendees, including a selected faculty of clinicians, academicians, regulators, and Industry representatives. The small nature of the meeting was considered essential for the exchange of ideas and to formulation of thoughts on future areas of research around coronary atherosclerosis.
Previous editions
VPM 2019
Guest Director: Prof. Wolfgang Koenig - Department of Cardiology, University of Ulm Medical School, Ulm, Germany.
Program VPM 2019
VPM 2018
VPM 2017
Guest Director: Prof. Panos E. Vardas - Department of Cardiology, University of Crete, Greece
Program VPM 2017
VPM 2016
Guest Director: Prof. Bernard Gersh - Mayo Clinic, USA
Program VPM 2016
Report Day 1
Report Day 2
Report Day 3
VPM 2015
Guest Director: Prof. Valentin Fuster - CNIC, Madrid & Mount Sinai Medical Center, NYC
Program VPM 2015
VPM 2014
Guest Director: Prof. Dorian Haskard - Imperial College London
Program VPM 2014
Structural Heart Core Lab
The Cardialysis Structural Heart Core Lab provides the perfect partner in conducting transcatheter therapies clinical trials (e.g. TAVR, TMTT). Over the past few years thousands of imaging data from patients enrolled in several registries and clinical trials have been successfully analyzed and adjudicated by the Cardialysis Core Lab. These data are used for CE mark and FDA submissions.
Investigator Initiated Studies
The European Cardiovascular Research Institute (ECRI) offers a platform for the design and conduct of international investigator-initiated clinical trials. ECRI acts as Sponsor ensuring compliance with ICH GCP guidelines and regulatory standards. Trial activities are executed by Cardialysis alone or in collaboration with renowned research organizations world-wide.
Monitoring Services
Cardialysis offers a consolidated monitoring network across Europe. Our clinical research associates ensure timely activation of investigational sites, high-quality data review and effective interaction with sites. With >1400 sites monitored and >200,000 patients included, Cardialysis has established a significant track record in site management.